Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
8 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06096220 | Usage of 5-fluorouracil and Carnoy's Solution in Surgical Treatment of Odontogenic Keratocysts | enrolling by invitation | Phase 4 | 50 | University of BelgradeOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04078152 | Durvalumab Long-Term Safety and Efficacy Study(WAVE) | completed | Phase 4 | 163 | AstraZenecaINDUSTRY | 31 | Dec 20, 2024 | clinicaltrials |
| NCT01739764 |
| An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol |
| completed |
| Phase 4 |
| 215 |
| Hoffmann-La RocheINDUSTRY |
| 25 |
| Jan 7, 2021 |
| clinicaltrials |
| NCT02500641 | Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout(FORWARD) | completed | Phase 4 | 196 | Menarini International Operations Luxembourg SAINDUSTRY | 6 | Jun 21, 2019 | clinicaltrials |
| NCT01180049 | Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma | completed | Phase 4 | 101 | PfizerINDUSTRY | 11 | May 20, 2019 | clinicaltrials |
| NCT02208843 | Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation | completed | Phase 4 | 60 | Boehringer IngelheimINDUSTRY | 7 | Dec 17, 2018 | clinicaltrials |
| NCT00949910 | An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 4 | 6,586 | Hoffmann-La RocheINDUSTRY | 51 | Oct 5, 2016 | clinicaltrials |
| NCT00451906 | A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer. | completed | Phase 4 | 2,252 | Hoffmann-La RocheINDUSTRY | 40 | May 24, 2016 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials